Consolidation Treatment With Y90-Ibritumomab Tiuxetan In Patients With High-Risk Follicular Lymphoma With Either Partial Or Complete Response To R[rituximab]-Chop Induction Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 14 May 2012 Status changed from recruiting to completed, according to the European Clincial Trials Dabase record.
- 19 Aug 2008 New trial record.